All In MedTech

FDA Clearance Tracker · P030002-S039

Trulign® Toric Posterior Chamber Intraocular Lens (IOL)

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Apr 8, 2022 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Apr 8, 2022

Approved

Time to decision

178 days

Received Oct 12, 2021. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P030002-S039
Device name
Trulign® Toric Posterior Chamber Intraocular Lens (IOL)
Applicant location
Irvine, CA
Received
Oct 12, 2021
Decided
Apr 8, 2022
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Labeling Change - PAS
Original approval
P030002

Device type

Device class
Class III
Regulation
21 CFR 886.3600
Specialty
Ophthalmology

Every decision under product code NAA

FDA's approval statement

As written in FDA's record.

Approval for revised device labeling to describe results of the New Enrollment Study Post Approval Study (PAS) protocol.

Source documents

Other decisions for Bausch & Lomb, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.